No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Distribution
Uniphar plc functions as a multifaceted healthcare solutions provider, serving markets across the Republic of Ireland, the United Kingdom, and various international territories. Its operations are segmented into three primary divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. The Commercial & Clinical division provides outsourced services encompassing sales, marketing, and integrated account management for pharmaceutical and medical device manufacturers, also managing the distribution and support for medical device producers. The Product Access division facilitates access to pharmaceutical and medical treatments through on-demand services, fostering vital connections between manufacturers and healthcare stakeholders; additionally, its exclusive access services establish tailored distribution agreements for crucial pharmaceutical brands. The Supply Chain & Retail division manages the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary practices, and also oversees a network of retail pharmacies operating under the Life, Allcare, and Hickey's banners. Beyond its core divisional activities, Uniphar delivers a broad spectrum of specialized services, including pharmacy support, comprehensive pharmaceutical supply chain management, specialist nursing and infusion services, medical device distribution, and healthcare technology solutions. It further extends its expertise through data intelligence, consultancy, pharmaceutical advisory, and medical affairs services, alongside online pharmacy operations, product fostering, and data analytics for the pharmaceutical sector. Established in 1967, Uniphar plc maintains its headquarters in Dublin, Ireland.
www.uniphar.ieNo one on the platform currently holds UPR.IR.
No tracked institution reports a position in UPR.IR as of their last filing.
No one on the platform has traded UPR.IR yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.1% | 9.5% | — | — | — | |
| Rev. Growth % | 11.0% | 11.0% | ||||
| Profit Margin % | 1.7% | 2.1% | 1.5% | |||
| Free Cash Flow Margin % | 1.5% | 1.6% | 1.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.2B | +8.4% | $0.27 | $0.26–$0.27 | — | 6 |
| 2027 | $3.4B | +5.1% | $0.28 | $0.27–$0.29 | — | 6 |
| 2028 | $3.6B | +5.0% | $0.30 | $0.27–$0.33 | — | 5 |
| 2029 | $3.8B | +6.9% | $0.34 | $0.33–$0.35 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-02-24 | $0.14 | $0.17 | +21.3% |
| 2025-09-05 | $0.09 | $0.10 | +4.3% |
| 2025-02-25 | $0.13 | $0.18 | +40.6% |
| 2024-09-03 | $0.08 | $0.08 | +0.0% |
| 2024-02-27 | $0.11 | $0.11 | -2.0% |
| 2023-09-14 | $0.08 | $0.07 | -6.2% |
| $1.4B |
| — |
| GALE.SWGalenica AG | $82.50 | -1.08% | $4.1B | — |
| GL9.IRGlanbia plc | $21.40 | -0.93% | $5.2B | — |
Source: Financial Modeling Prep · peers by sector/industry